Evidence map›Paper›PMID 31743427›Full record

ReviewCancer2020

Patient-reported outcomes in the Translational Breast Cancer Research Consortium.

Deborah J Bowen, Eileen H Shinn, Sophie Gregrowski, Gretchen Kimmick, Laura S Dominici, Elizabeth S Frank, Karen Lisa Smith, Gabrielle Rocque, Kathryn J Ruddy, Teri Pollastro and 4 more

Abstract readReview
In one paragraph

Review in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Deborah J BowenDepartment of Bioethics and Humanities, University of Washington, Seattle, Washington.ORCID 0000-0003-2420-4422
Eileen H ShinnThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Sophie GregrowskiUniversity of Washington, Seattle, Washington.
Gretchen KimmickDepartment of Medicine, Duke Cancer Institute, Durham, North Carolina.
Laura S DominiciDana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, Massachusetts.
Elizabeth S FrankDana-Farber Cancer Institute, Boston, Massachusetts.
Karen Lisa SmithSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-6687-0119
Gabrielle RocqueUniversity of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama.ORCID 0000-0003-4188-9785
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.
Teri PollastroUniversity of Washington, Seattle, Washington.
Michelle MeliskoUniversity of California at San Francisco, San Francisco, California.
Tarah J BallingerIndiana University School of Medicine, Indianapolis, Indiana.
Oluwadamilola M FayanjuDepartment of Surgery, Duke Cancer Institute, Durham, North Carolina.ORCID 0000-0002-0876-975X
Antonio C WolffSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-3734-1063

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
Institutional Career Development CoreKL2TR002554 · NCATS · DUKE UNIVERSITY · PI SVETKEY, LAURA P · 2018 to 2022
$8.2M
Duke CTSA (Composite)KL2TR001115 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, KRAFT, MONICA · 2013 to 2017
$5.1M
Using Modifiable Risk Factors to Predict Inferior Care and Survival after Breast Cancer Diagnosis: A Novel Approach to Addressing Health DisparitiesK08CA241390 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FAYANJU, OLUWADAMILOLA M. · 2019 to 2023
$1.1M
NCATS NIH HHS KL2 TR001115NCATS NIH HHS KL2 TR002554NCATS NIH HHS UL1 TR002553NCI NIH HHS K08 CA241390NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

Members of the Translational Breast Cancer Research Consortium conducted an expert-driven literature review to identify a list of domains and to evaluate potential measures of these domains for inclusion in a list of preferred measures. Measures were included if they were easily available, free of charge, and had acceptable psychometrics based on published peer-reviewed analyses. A total of 22 domains and 52 measures were identified during the selection process. Taken together, these measures form a reliable and validated list of measurement tools that are easily available and used in multiple cancer trials to assess patient-reported outcomes in relevant patients.

Indexed as

Patient Reported Outcome MeasuresQuality of LifeBreast NeoplasmsClinical Trials as TopicFemaleHumansSurveys and Questionnairesbreast cancer consortiumbreast cancer treatmentclinical trialspatient-reported outcomestranslational clinical judgements

Identifiers

PMID31743427
PMCPMC7063688

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.